Theravance has posted a net loss of $21.22m for the third quarter 2010, or $0.29 loss per diluted share, compared to a net loss of $22.18m, or $0.35 loss per diluted share, for the comparable period in 2009.
Loss from operations was $19.85m, compared to $21.08m for the comparable period in 2009.
For the nine months ended 30 September 2010, Theravance has posted a revenue of $17.28m, compared to $20.55m for the year ago period.
For the nine months ended 30 September 2010, Theravance has posted a net loss of $64.56m, or $0.91 loss per diluted share, compared to net loss of $63.09m, or $1 loss per diluted share, for the year ago period.
Loss from operations was $60.39m, compared to $60.78m for the year ago period.
Theravance CEO Rick Winningham said that the Relovair Phase 3 programs in COPD and asthma are progressing well and have now enrolled over 8,000 patients.
Theravance is a biopharmaceutical company focused on the discovery, development and commercialisation of small molecule medicines across a number of therapeutic areas including respiratory disease, bacterial infections and gastrointestinal motility dysfunction.